FDA approves Boston Scientific's thrombectomy system:
This article was originally published in Clinica
The US FDA has approved Boston Scientific's Oasis thrombectomy system is designed to remove blood clots which develop in the access grafts of haemodialysis patients. A low-pressure water jet breaks down the blood clot and washes away the debris from the haemodialysis graft. The system can be used with a standard angiographic injector, said the company.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.